Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology announced that Chief Medical Officer Phil Pang, M.D., Ph.D., will present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Conference on October 13 at 9:30 a.m. PT / 12:30 p.m. ET. A live webcast will be available via the Investors section of the Vir website and will be archived for 30 days post-event.
Vir focuses on using advanced technologies to combat serious infectious diseases, with ongoing projects targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its Chief Medical Officer, Phil Pang, M.D., Ph.D., will present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on October 6, 2021, at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page and archived for 30 days. Vir focuses on immunological solutions for infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that CEO George Scangos, Ph.D., will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 9:30 a.m. PT / 12:30 p.m. ET. Investors can access a live webcast from the Investors section of the Vir website, which will also be archived for 30 days after the event. The company emphasizes the importance of monitoring its website for material information and updates on its development pipeline, which focuses on serious infectious diseases.
Vir Biotechnology announces that CFO Howard Horn will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 a.m. PT / 7:00 a.m. ET. The presentation will be available via live webcast on the company's website and archived for 30 days.
Vir focuses on leveraging immunologic insights and technology to combat infectious diseases, with a development pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology has received the first marketing authorization for its monoclonal antibody, sotrovimab, in Australia. This approval from the Australian Therapeutic Goods Administration allows sotrovimab, branded as Xevudy®, to be used in adults and adolescents with COVID-19 at risk of severe outcomes. Sotrovimab has already been authorized for emergency use in the U.S. and received favorable opinions in other regions. Vir is collaborating with GlaxoSmithKline to distribute sotrovimab, which shows efficacy against current SARS-CoV-2 variants.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced robust second-quarter 2021 results, achieving total revenues of $177.1 million, a significant increase from $67.0 million YoY. Key developments include the emergency use authorization of monoclonal antibody sotrovimab for high-risk COVID-19 patients and positive data showing its efficacy against prevalent variants. The company also advanced its hepatitis B portfolio, initiating multiple clinical trials. Notably, net income reached $61.8 million, or $0.48 per share, reversing a loss from the previous year.
Vir Biotechnology and GlaxoSmithKline have entered a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, a monoclonal antibody treatment for COVID-19. This agreement aims to provide rapid access to sotrovimab for high-risk patients in participating EU Member States. Sotrovimab has shown a 79% reduction in hospitalizations/deaths in clinical trials. The companies are also pursuing ongoing evaluations to ensure effectiveness against new virus variants, emphasizing the urgent need for effective treatments amid the ongoing pandemic.
Vir Biotechnology (Nasdaq: VIR) announced it will provide a corporate update along with its financial results for Q2 2021 on August 5, 2021. The press release will be accessible after market close on their website. Vir focuses on combining immunologic insights with advanced technologies to combat serious infectious diseases, with a development pipeline that includes candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology announced on July 15, 2021, that the first patient has been dosed in the Phase 2 MARCH trial for VIR-2218 and VIR-3434, targeting chronic hepatitis B infection. This trial aims to assess the safety and efficacy of these investigational therapies, aiming for a functional cure in approximately 90 patients. The combination approach is expected to restore immune response against HBV, with primary endpoints focusing on treatment-emergent adverse events and achieving undetectable HBsAg. Both drugs utilize novel technologies that could enhance treatment effectiveness.
Vir Biotechnology announced promising results from Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 for chronic hepatitis B virus (HBV). Both therapies exhibited positive safety profiles and significant reductions in hepatitis B surface antigen (HBsAg). VIR-2218 showed dose-dependent HBsAg reductions and enhanced results when combined with pegylated interferon alfa. The Phase 1 trial of VIR-3434 indicated rapid HBsAg declines with no new safety concerns. A combination trial of both therapies is expected to start in the latter half of 2021.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
